Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.

Tobin NP, Lindström LS, Carlson JW, Bjöhle J, Bergh J, Wennmalm K.

Mol Oncol. 2014 May;8(3):741-52. doi: 10.1016/j.molonc.2014.02.007. Epub 2014 Feb 28. Erratum in: Mol Oncol. 2014 Sep 12;8(6):1159.

2.

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.

JAMA Oncol. 2016 Feb;2(2):217-24. doi: 10.1001/jamaoncol.2015.4377.

PMID:
26633571
3.

Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.

Niikura N, Iwamoto T, Masuda S, Kumaki N, Xiaoyan T, Shirane M, Mori K, Tsuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y.

Cancer Sci. 2012 Aug;103(8):1508-12. doi: 10.1111/j.1349-7006.2012.02319.x. Epub 2012 Jun 14.

4.

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.

Bertucci F, Finetti P, Roche H, Le Doussal JM, Marisa L, Martin AL, Lacroix-Triki M, Blanc-Fournier C, Jacquemier J, Peyro-Saint-Paul H, Viens P, Sotiriou C, Birnbaum D, Penault-Llorca F.

Ann Oncol. 2013 Mar;24(3):625-32. doi: 10.1093/annonc/mds510. Epub 2012 Nov 1.

PMID:
23117074
5.

Prognostic applications of gene expression signatures in breast cancer.

Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A.

Oncology. 2009;77 Suppl 1:2-8. doi: 10.1159/000258489. Epub 2010 Feb 2. Review.

PMID:
20130425
6.

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.

Lundberg A, Lindström LS, Harrell JC, Falato C, Carlson JW, Wright PK, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP.

Clin Cancer Res. 2017 Dec 15;23(24):7512-7520. doi: 10.1158/1078-0432.CCR-17-1535. Epub 2017 Sep 29.

PMID:
28972043
7.

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. doi: 10.1093/jnci/djp082. Epub 2009 May 12.

8.

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.

Karlsson E, Delle U, Danielsson A, Olsson B, Abel F, Karlsson P, Helou K.

BMC Cancer. 2008 Sep 8;8:254. doi: 10.1186/1471-2407-8-254.

9.

Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.

Yuan JP, Wang LW, Qu AP, Chen JM, Xiang QM, Chen C, Sun SR, Pang DW, Liu J, Li Y.

PLoS One. 2015 Apr 9;10(4):e0122734. doi: 10.1371/journal.pone.0122734. eCollection 2015.

10.

Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.

Joshi S, Watkins J, Gazinska P, Brown JP, Gillett CE, Grigoriadis A, Pinder SE.

BMC Cancer. 2015 Jul 25;15:546. doi: 10.1186/s12885-015-1531-3.

11.
12.

Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling.

Frings O, Augsten M, Tobin NP, Carlson J, Paulsson J, Pena C, Olsson E, Veerla S, Bergh J, Ostman A, Sonnhammer EL.

Am J Pathol. 2013 Jun;182(6):2037-47. doi: 10.1016/j.ajpath.2013.02.018. Epub 2013 Apr 10.

PMID:
23583284
13.

Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?

Lin CH, Lu YS, Huang CS, Kuo KT, Wang CC, You SL, Lin PH, Chang DY, Kuo WH, Chang KJ, Cheng AL.

J Clin Pathol. 2011 Sep;64(9):781-7. doi: 10.1136/jclinpath-2011-200064. Epub 2011 Jun 4.

PMID:
21642658
14.

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.

Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer JU, Budczies J, Mehta KM, von Minckwitz G.

Ann Oncol. 2013 Nov;24(11):2786-93. doi: 10.1093/annonc/mdt350. Epub 2013 Aug 22.

PMID:
23970015
15.

Bcl2 and Ki67 refine prognostication in luminal breast cancers.

Chen LY, Tsang JY, Ni YB, Chan SK, Chan KF, Zhang S, Tse GM.

Breast Cancer Res Treat. 2015 Feb;149(3):631-43. doi: 10.1007/s10549-015-3288-4. Epub 2015 Feb 4.

PMID:
25648135
16.

Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Iwamoto T, Kelly C, Mizoo T, Nogami T, Motoki T, Shien T, Taira N, Hayashi N, Niikura N, Fujiwara T, Doihara H, Matsuoka J.

Clin Breast Cancer. 2016 Apr;16(2):95-100.e1. doi: 10.1016/j.clbc.2015.10.004. Epub 2015 Nov 10.

PMID:
26631838
17.

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.

Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, Fernö M; South Sweden Breast Cancer Group.

Mod Pathol. 2010 Feb;23(2):251-9. doi: 10.1038/modpathol.2009.167. Epub 2009 Nov 20.

18.

Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.

Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM.

Breast Cancer Res Treat. 2013 Jan;137(1):57-67. doi: 10.1007/s10549-012-2296-x. Epub 2012 Nov 8.

PMID:
23135572
19.

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.

20.

A signature inferred from Drosophila mitotic genes predicts survival of breast cancer patients.

Damasco C, Lembo A, Somma MP, Gatti M, Di Cunto F, Provero P.

PLoS One. 2011 Feb 28;6(2):e14737. doi: 10.1371/journal.pone.0014737.

Supplemental Content

Support Center